Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 23;9:682261. doi: 10.3389/fcell.2021.682261

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Qian, Li, Xie, Lu, Li, Wang, Tang, Shi, Jiang, Li, Chen, Peng, Xu, Deng and Shen.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Benefit of gemcitabine-based chemotherapy among patients in high and low score groups. (A) The gemcitabine resistance related gene set was significantly enriched in the low score group of TCGA cohort by GSEA analysis. The green curve represents enrichment score (ES). The highest point was used to represent ES value in gemcitabine resistance pathway. The ES value indicates the correlation between gene and gemcitabine resistance pathway. The black bar codes represent genes in gemcitabine resistance pathway and these genes were ordered according to their expression levels. The left end or right end genes are leading edge subset strongly contributed to ES value. The bottom numbers represent the order of expression levels in the genome from highest to lowest. (B) The 198 gemcitabine resistance-related genes were significantly attenuated in high score group of TCGA cohort (p < 0.05). Patients from the (C) TCGA database (n = 173) and (D) Ruijin cohort (n = 101) are divided into four groups (TCGA, Low score non-chemotherapy, n = 17, Low score chemotherapy, n = 36, high score non-chemotherapy, n = 45, high score chemotherapy, n = 75; Ruijin, Low score non-chemotherapy, n = 23, Low score chemotherapy, n = 15, high score non-chemotherapy, n = 34, high score chemotherapy, n = 29) and then Kaplan-Meier survival curves were plotted.